Analyst Ratings for Intra-Cellular Therapies (ITCI)
ITCI Rating Summary
ITCI Price Target Summary
- Highest: $107.00 (Canaccord Genuity)
- Lowest: $62.00 (JPMorgan)
- Average: $89.38
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$89.38 (+22.2%)
* Over Last 12-Mos
Rating Score: 8.5 / 10
Percentile Rank: 87%
Avg. $ Target:
$89.38 (+22.2%)
* Over Last 12-Mos
Rating Score: 8.5 / 10
Percentile Rank: 87%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/3/2024 | Baird » Updated 4/17/2024 |
Joel Beatty | New Coverage | Outperform (N/A) |
103.00 (83.00) |
71.62 (73.12) |
2.09% | Details |
| 12/11/2023 | TD Cowen » Updated 4/16/2024 |
Joseph Thome | New Coverage | Buy (N/A) |
90.00 (80.00) |
60.29 (73.12) |
21.28% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
